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Atherosclerotic cardiovascular disease is a prevalent human disorder and a signiﬁcant cause of human
morbidity and mortality. A number of risk factors may predispose an individual to developing atheroscle-
rosis, and of these factors, cigarette smoking is strongly associated with the development of cardiovascu-
lar disease. Current thinking suggests that exposure to toxicants found in cigarette smoke may be
responsible for this elevated disease likelihood, and this gives rise to the idea that reductions in the levels
of some smoke toxicants may reduce the harm associated with cigarette smoking. To assess the disease
risk of individuals who smoke cigarettes with altered toxicant levels, a weight-of-evidence approach is
required examining both exposure and disease-related endpoints. A key element of such an assessment
framework are data derived from the use of in vitro models of cardiovascular disease, which when con-
sidered alongside other forms of data (e.g. from clinical studies) may support evidence of potential
reduced risk. Importantly, such models may also be used to provide mechanistic insight into the effects
of smoking and of smoke toxicant exposure in cardiovascular disease development. In this review the use
of in vitro models of cardiovascular disease and one of the contributory factors, oxidative stress, is dis-
cussed in the context of assessing the risk potential of both conventional and modiﬁed cigarettes. Prac-
tical issues concerning the use of these models for cardiovascular disease understanding and risk
assessment are highlighted and areas of development necessary to enhance the power and predictive
capacity of in vitro disease models in risk assessment are discussed.
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Atherosclerosis is the predominant form of cardiovascular dis-
ease and is an inﬂammatory disorder which ultimately causesfax: +44 (0)2380 793076.
-NC-ND license.the formation of blockages (lesions) in arterial blood vessels. This
gives rise to a compromised blood supply to tissues and organs
which reduces the delivery of oxygen and nutrients to respiring
cells and induces pathogenic changes in cell function. The presence
of lesions leads to both chronic and acute clinical manifestations
which differ depending on the degree of blockage caused and also
514 I.M. Fearon et al. / Toxicology in Vitro 27 (2013) 513–522on the site of the lesion. It is these manifestations that have made
atherosclerotic cardiovascular disease a major cause of morbidity
and mortality worldwide.
Atherosclerotic lesion formation involves a complex cascade of
inﬂammatory processes (Ross, 1999; Libby et al., 2002; Rader and
Daugherty, 2008). An initiating step in atherosclerosis develop-
ment is damage to the arterial endothelium (Hadi et al., 2005), a
monolayer of cells which lines blood vessels and regulates many
aspects of vascular function and reactivity. Endothelial damage
triggers a chronic inﬂammatory process in the vessel which even-
tually involves a host of different cell types within the cardiovascu-
lar system including monocytes/macrophages, vascular smooth
muscle cells and platelets (Fearon and Faux, 2009). The multicellu-
lar complexity of atherosclerosis is an important determinant of
which in vitro models are most suitable to examine the mecha-
nisms underlying cardiovascular disease in the laboratory.2. Risk factors for cardiovascular disease
The possibility of an individual developing cardiovascular dis-
ease can be impacted by a number of risk factors including genet-
ics, age, menopausal status, gender, high–calorie and high–fat diet,
smoking, concurrent disease status (e.g. diabetes), alcohol con-
sumption and lack of physical activity (Mozaffarian et al., 2008).
With respect to smoking as a risk factor, it has long been acknowl-
edged that the use of combustible tobacco products elevates the
likelihood of an individual developing cardiovascular disease (Ros-
amond et al., 2007). This may be linked to exposure to one (or a
combination) of a number of cigarette smoke toxicants which
modify the activity and function of cells within the cardiovascular
system and initiate pathogenic processes. Cigarette smoke is a
complex mixture composed of more than 5,600 chemicals (Perfetti
and Rodgman, 2011). Within this unique matrix, several chemicals
have been identiﬁed as toxicants and are thought to drive disease
processes (Hoffman and Hecht, 1990). While attempts have been
made to identify those compounds that have the greatest risk of
inducing disease, no single toxicant or group of toxicants has been
identiﬁed as the inducer of cardiovascular disease processes. Spe-
ciﬁc smoke constituents have been administered to animal models
of cardiovascular disease in order to assess their effects on athero-
sclerotic lesion development (O’Toole et al., 2009; Srivastava et al.,
2011). However, a single compound behaves much differently in a
simple state than when it is combined with >5,600 unique com-
pounds with unique properties (e.g., free radicals, antioxidants,
toxicants). Moreover, it is further likely that direct interactions
with compounds in the complex smoke mixture may have mitigat-
ing effects.
Since the identity of the compound(s) in cigarette smoke that
drive lesion progression remains elusive, an approach that has re-
ceived considerable attention of late has been the development of
potentially reduced-exposure products (PREP). In 2001, the US
Institute of Medicine reported that, since smoking-related diseases
were dose related, and because epidemiological studies show
reduction in the risk of smoking-related diseases following cessa-
tion, it might be possible to reduce smoking-related risks by devel-
oping PREPs (Stratton et al., 2001). In this report a framework was
proposed for the assessment of the biological effects of cigarettes
with modiﬁed yields of smoke toxicants. An important component
of this approach to product evaluation is the use of in vitro models
of smoking-related diseases, including cardiovascular disease.
Alongside data from other studies (smoke chemistry evaluation,
clinical studies examining biomarkers of both exposure and of bio-
logical effect, in vitro and in vivo toxicological studies, in vivo mod-
els of disease and epidemiological studies), ﬁndings made using
in vitro disease models would form part of a weight-of-evidenceapproach to evaluate and support any proposed change in biolog-
ical effect. What is lacking from this framework is a detailed insight
into not only which models to use but how they would form a part
of the overall evaluation framework. In the following sections,
in vitro models and cigarette smoke exposure that may be used
to examine the cardiovascular disease potential of tobacco prod-
ucts with modiﬁed smoke toxicant yields are discussed.
3. In vitro models and product assessment – why use them?
The use of pre-clinical tools for product assessment or funda-
mental, mechanistic research is generating much scientiﬁc interest
while gaining additional regulatory importance (Hartung and Das-
ton, 2009). The use of in vitro disease models offers valuable mech-
anistic insights into disease development and progression and
provides efﬁcient platforms for product screening. There are a
wealth of choices when considering the implementation of
in vitro models of disease as part of a pre-clinical assessment
framework, and such models can not only support an assessment
framework for modiﬁed tobacco products but also for other con-
sumer goods such as cosmetics and putative drug candidates
(e.g. Bauch et al., 2011).
With in vitro models, total body or systemic inﬂuences, such as
the extracellular milieu, are removed. The in vitromodel, by design,
sets aside the tissue of interest from the rest of the body. For this
reason, the in vitro test system as it relates to and responds com-
pared to in vivo tissues must be fully considered. For example, an
in vitro protocol may successfully identify whether a test agent is
an irritant or a cellular toxicant, but because the assays are per-
formed in comparative isolation, an in vitro model does not neces-
sarily predict risk. However, less complex systems can provide
advantages including providing the ability to manipulate and
reproduce disease mechanisms using advanced molecular biologi-
cal techniques to further understand disease pathology. Further-
more, if in vivo work is required to validate ﬁndings from an
in vitro model, data from the in vitro studies may help to reﬁne
the experimental design and as such assist in the reduction in ani-
mal usage.
Since the publication of the National Research Council’s ‘‘Toxic-
ity Testing in the 21st Century: A Vision and a Strategy’’ (National
Research Council, 2007) there have been many advances in in vitro
toxicity and disease testing for human health assessment. In vitro
evaluation of modiﬁed biochemical pathways and the evaluation
of dose–responses over relevant concentration ranges are key as-
pects of the vision. Also of importance is consideration of the origin
of cells used in the development and implementation of a given
model. Variation exists between the same cell type but originating
from different species, and therefore the choice of cell origin is an
important consideration. For example, a recent study by Nemmar
et al., (2012) highlighted species differences in the effects of diesel
exhaust particulate on in vitro erythrocyte lipid peroxidation as
well as the activity of oxidant/antioxidant systems. Differences in
oxidative stress responses have also been reported by others in
endothelial cells from different species (e.g. Ram and Hiebert,
2004) and intriguingly, even the use of different media types
may accentuate these differences (Ram and Hiebert, 2001). Intra-
species differences also need to be taken into consideration since,
for example, in vitro platelet aggregation differs in cells from differ-
ent mouse strains (Paigen et al., 1987). There has been a major shift
in researchers employing human-derived cells and tissues for
in vitromodel development. A prominent rationale for this is to en-
sure the maintenance of as many physiologically-relevant param-
eters as possible in the in vitro test system. The use of such cells
may further provide a means of standardising responses and limit-
ing the effects of species differences on experimental variability
(Imegwu et al., 2001).
Table 1
Advantages and disadvantages of using in vitro models as part of an assessment framework for modiﬁed risk tobacco products. Modiﬁed from Hartung and Daston, 2009.
Advantages Disadvantages
Metabolism Unable to directly/easily extrapolate results back to human disease
Simplicity Over-interpretations
Inexpensive Erroneous conclusions
Miniaturisation Unable to replicate cellular microenvironment
Reduces animal use No systemic homeostatic mechanisms present
High-number of replicates Artiﬁcial
Fast/high throughput and generate reproducible data May not be able to reproduce complex mixtures in test environment
Human tissues/cells available for in vitro studies, allowing easier
extrapolation to human disease
Physiological conditions not present (e.g. temperature, electrolytes, paracrine and intracellular
signalling)
Automation Single cell type (usually)
Cell models available for most tissue types Primary cells exhibit donor variability and their genotypic/phenotypic background may be
unknown
Avoidance of animal species variation Models not validated or qualiﬁed
immortalised (continuous) cell lines support reproducibility and
facilitate inter-lab comparisons
Appropriate exposure protocol (acute or chronic, test agents – total particulate matter, aqueous
cigarette smoke extracts, whole smoke, gas phase)
Lack of metabolic capacity
Growth conditions optimised for rapid growth
I.M. Fearon et al. / Toxicology in Vitro 27 (2013) 513–522 515While in vitro models are by their very nature imperfect substi-
tutes for examining human disease processes, they do offer a sig-
niﬁcant number of advantages compared to in vivo approaches
using animal models of disease (Table 1). It is important to note
that these advantages and disadvantages may also differ for each
in vitro model. However, it is generally accepted that if the models
are more representative of the whole organ (as it naturally func-
tions and with the endogenous cell types), the predictive capacity
and accuracy of data obtained using these models will be greater.4. Which cardiovascular disease in vitro models are most
appropriate for use?
The complexity of atherosclerotic cardiovascular disease, in
terms of the many different cell types involved and the multitude
of cellular processes which may be affected by cigarette smoke
makes choosing the relevant in vitro disease models challenging.
Given this complexity, one single in vitro model would not be able
to replicate the entire pathogenesis of the disease and several mod-
els may be needed to cover a wide spectrum of different cell types
and cellular processes. Thus, in much the same way as for a com-
plete product assessment framework itself such as that proposed
by the Institute of Medicine (Stratton et al., 2001), data from a
number of in vitro models of different disease processes should
be utilised in an integrated weight-of-evidence approach. It is also
noteworthy that many disease processes, such as vascular calciﬁ-
cation, do not lend themselves well to the development of models.
These limitations must be taken into account when selecting mod-
els for the purpose of assessment.
Due to the underlying role of the vascular endothelium in dis-
ease initiation and development, many studies have focussed on
this cell type to develop disease-relevant models. The expression
of a number of genes and gene products is altered in endothelial
cells exposed to cigarette smoke extracts. A number of these genes
are directly related to pathogenic processes in humans and have
also been used as biomarkers of biological effect in clinical studies,
and this enhances the relevance of data from this model. For exam-
ple, exposure of endothelial cells to cigarette smoke extracts in-
duces the expression of the adhesion molecules intercellular
adhesion molecule 1 (ICAM-1), E-selectin (Chen et al., 2009) and
vascular cell adhesion molecule 1 (VCAM-1; Shen et al., 1996).
These markers have been used in clinical studies examining bio-
marker levels in those who quit smoking (Halvorsen et al., 2007;
Reichert et al., 2009). The levels of adhesion molecule proteins
can be examined in any number of ways, including PCR-based ap-
proaches for gene expression, ELISA-based techniques to examineprotein expression and immunocytochemistry to explore protein
expression and localization.
Endothelial damage has been considered a primary cardiovas-
cular disease-initiating step (Hajjar et al., 1981; Gimbrone et al.,
2000; Schulz et al., 2004; Hadi et al., 2005) and healthy, native
endothelial cells are suggested to impart a repair capacity on the
damaged endothelium. With this in mind, functional in vitro assays
may be used to examine endothelial damage and repair and to as-
sess their potential impact on cardiovascular disease initiation and
progression. For example, an endothelial scratch wound model has
been used. In this model, a conﬂuent monolayer of endothelial cells
is ‘damaged’ using a pipette and migration then observed by
phase-contrast microscopy (Acheampong et al., 2009). This model
was sensitive to cigarette smoke extracts (Acheampong et al.,
2009; Fearon et al., 2011) as well as to human sera from smokers
(unpublished data), both of which inhibited endothelial migration.
This model can also distinguish between cigarette smoke with dif-
ferent toxicant contents, which demonstrates its potential use as a
PREP assessment tool (Fearon et al., 2011). Similar endothelial
migration assays have been developed utilising a Boyden chamber,
in which endothelial migration was assessed by monitoring che-
motactic cell passage through a micropore membrane (Michaud
et al., 2006). Both of these assays bear relevance to smoking-in-
duced cardiovascular disease and as such are of potential use for
PREP assessment.
Another functional assay with relevance to cardiovascular dis-
ease is the endothelial angiogenesis assay. Angiogenesis is a pro-
cess by which new blood vessels are formed from the existing
vasculature, and is not only a pathologic component of atheroscle-
rotic plaque stability but is also a physiological process involved in
coronary tissue reperfusion following ischaemic events (Freedman
and Isner, 2001; Al Sabti, 2007). Angiogenesis is further critical to
the restoration of the blood supply to the brain, which is beneﬁcial
following ischaemic stroke (Chopp et al., 2007). The processes
underlying angiogenesis are complex, and involve endothelial pro-
liferation (to provide enough cells to form the new vessel), migra-
tion, differentiation and structural re-arrangement (tube
formation; Staton et al., 2004). Although no single model can com-
pletely re-create the angiogenic process, there are many excellent
in vivo and in vitromodels which reproduce one or more of the pro-
cesses involved in angiogenesis. With respect to in vitro models,
these include endothelial proliferation assays (using MTT or simi-
lar dyes, tritiated thymidine, or bromodeoxyuridine), wound heal-
ing or Boyden chamber or migration assays, and 2D and 3D matrix
tube formation assays (Auerbach et al., 2003; Michaud et al., 2006;
Staton et al., 2004) utilising Matrigel as a growth substrate. Ciga-
rette smoke extracts have been shown to impair in vitro angiogen-
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and this correlated well with the in vivo response in a mouse hind-
limb ischaemia (Michaud et al., 2003) and chick embryo (Ejaz et al.,
2009) models of angiogenesis.
The migration of vascular smooth muscle cells from the medial
layer into the intimal layer of the vessel wall and their subsequent
proliferation is a key event in the thickening of the vessel wall in
atherosclerosis (Tsaousi et al., 2011) and this is enhanced in smok-
ers (Fitch et al., 2011). In vitro, cultured smooth muscle cells have
been used to demonstrate the proliferative effects of cigarette
smoke extracts (e.g. Chen et al., 2010). The chemotactic movement
of smooth muscle cells towards a chemical stimulus can also be
modelled in vitro, again using a vertical Boyden chamber assay in
which migrated cells can be stained and counted (Yoshiyama
et al., 2011) or a horizontal migration (scratch wound; Di Luozzo
et al., 2005) assay. Such migration is sensitive to cigarette smoke
extracts (Yoshiyama et al., 2011) but caution must be taken whenFig. 1. An example microﬂuidics cellular perfusion system used to expose cells to pro-ath
are grown in clear microslides (A) which permit both real-time and post-experimental im
series of these microslides are attached to computer-controlled pumps (B) which allo
atherosclerotic ﬂow patterns. Both the pumps and microslides are small enough to be pl
(12 ml; (C) facilitate the measurement of proteins secreted by the cells following expe
(e.g. monocytes) can be introduced into these reservoirs in order to perform adhesion as
allow gene expression studies to be performed. From Cockcroft et al. (2009).interpreting such studies since nicotine itself is also a strong stim-
ulant for in vitro smooth muscle proliferation and migration (Di
Luozzo et al., 2005; Cucina et al., 2008; Yoshiyama et al., 2011;
Stein et al., 2011).
In healthy arteries, homeostatic mechanisms exist making the
surface of the endothelium unattractive to platelets and blood
monocytes. However, injury to the endothelium results in a cas-
cade of events that both induces platelet activation and attracts
immune cells to the site of injury (Hadi et al., 2005). Cigarette
smoking has been shown to alter endothelial function and the acti-
vation state of platelets as evidenced by elevations of adhesion
molecules (sVCAM, sICAM; Blann et al., 1997) and pro-thrombotic
proteins including vonWillebrand factor (MaCallum, 2005). In vitro
assays that assess the binding of platelets to either a substrate (Bel-
lavite et al., 1994) or an endothelial monolayer under shear ﬂow
conditions (Conant et al., 2009) are currently being developed
and optimised for the assessments of PREP and PREP extracts.erosclerotic ﬂow patterns and other interventions in vitro. Cultured endothelial cells
aging of cells by phase-contrast and immunoﬂuorescence microscopy techniques. A
w the ﬂow of media in both directions through the microslides, generating pro-
aced in a culture incubator. The small volumes of media in the perfusion reservoirs
rimental interventions using ELISA-based techniques. Additionally, other cell types
says. Finally, cells may be isolated from the microslides following the experiment to
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examined using in vitro techniques. In a study by Weber et al.
(1996), monocytes isolated from smokers showed increased bind-
ing to a monolayer of endothelial cells compared to those isolated
from control subjects. This observation would suggest that circu-
lating blood monocytes from smokers may be in an elevated state
of ‘‘activation’’. Thus a primitive measure of the effect of cigarette
smoking can be explored under static cell culture systems. Similar
techniques may be used to assess the effects of PREP tobacco ex-
tracts on monocyte binding. Currently, one of our laboratories is
exploring additional assays to assess monocyte binding under con-
ditions that mimic ﬂow types found in healthy and diseased arter-
ies (Cockcroft et al., 2009), which in essence re-creates vascular
physiology in an in vitro system.
Development of the ﬁrst grossly visible atherosclerotic lesion
(fatty streak lesion) is characterised by the presence of macrophage
foam cells. The initial recruitment of blood monocytes, their differ-
entiation to macrophages and their subsequent progression to
foam cells is well described (Ross, 1999). The presence of free rad-
icals in cigarette smoke is thought to contribute to the modiﬁca-
tion of lipids and lipoproteins, which results in their increased
recognition and uptake by macrophages. Studies by Yokode et al.
(1988, 1994) have shown that low density lipoprotein (LDL) expo-
sure to an aqueous extract of cigarette smoke signiﬁcantly in-
creases lipid droplets (as measured with oil red O staining) and
the concentration of cholesteryl ester in cultured macrophages.
The lipoprotein particles were shown to be extensively modiﬁed
while control particles were protected by superoxide dismutase;
however, thiobarbituric acid-reactive substances (TBARS) were
similar with and without exposure to aqueous extracts of cigarette
smoke. Expanding on these early studies is necessary to
understand the role of reactive oxygen species on lipoprotein
modiﬁcation resulting in lipoprotein uptake by macrophages. Fur-
thermore, this type of in vitro assay is anticipated to have the
capacity to differentiate between tobacco extracts prepared from
traditional cigarettes, PREPs and smokeless tobacco products.
Regardless of the actual model being used, one potential criti-
cism of in vitro cardiovascular disease cell culture models is the
nature of their culture under static conditions. In vivo, endothelial
cells are exposed to haemodynamic stress imparted on the vessel
wall by the ﬂowing blood. This stress is not a phenomenon found
equally at all points in the vascular tree and both ex vivo and
in vivo studies have provided support for the association of in-
creased haemodynamic stress found at branch points and curva-
tures in arteries with increased susceptibility to atherosclerotic
lesion formation at these sites (Cockcroft et al., 2009). Ideally,
in vitro models would allow for the exposure of endothelial cells
under ﬂow conditions which would mimic those found in vivo.
Such models are technically difﬁcult to develop. Although a num-
ber of systems allow for the culture of endothelial cells under ﬂow
conditions there are drawbacks to such an approach. One draw-
back is the large volumes of media required for peristaltic ﬂow
pumps which precludes the measurement of inﬂammatory factors.
Another is the potential for artefactual mechanical activation of
cardiovascular cells in these systems (Cockcroft et al., 2009). A
microﬂuidics perfusion system (Fig. 1) with the capability of
exposing endothelial cells in culture to pro-atherosclerotic ﬂow
proﬁles can be used to overcome these technical issues. The nature
of a microﬂuidics system can permit multi-endpoint studies to be
performed in a single experiment. These include the ability to mea-
sure secreted inﬂammatory proteins and biomarkers in the culture
media, to characterise protein expression and localisation using
immunocytochemistry and to perform functional assays in which
monocytes are allowed to adhere to an activated endothelial layer,
and this adherence is quantiﬁed using phase-contrast microscopy
(Cockcroft et al., 2009). This model demonstrated that simulatedpro-atherosclerotic ﬂow conditions sensitised the endothelial
monolayer to inﬂammatory activation and as such promises great
potential not only in advancing our understanding of the interac-
tion of cigarette smoke with a more physiologically-relevant
in vitro endothelial cell layer but also in providing a testing tool
with which to examine changes in biological activity when modi-
fying cigarette toxicant yields.5. In vitro models of inﬂammation and oxidative stress
Inﬂammation and oxidative stress are key contributing factors
in the development of atherosclerotic lesions (Fearon and Faux,
2009). Much evidence exists to support the hypothesis that the
production of oxygen free radicals (also termed reactive oxygen
species or ROS) plays a pivotal role in atherosclerotic lesion forma-
tion (Fearon and Faux, 2009). Because of this evidence, models of
these underpinning processes are useful additions to the suite of
in vitro models used to examine the biological effects of tobacco
smoke. Within the cardiovascular system, cellular enzyme systems
are potential sources of free radicals which can contribute to oxida-
tive stress. These include the mitochondrial electron transport
chain, NADPH oxidase and other cellular enzyme systems such as
nitric oxide synthase, xanthine oxidase and lipoxygenases (Fearon
and Faux, 2009). Contributions to cellular oxidative stress may also
be provided by the regulation of antioxidant systems including
glutathione peroxidase-1, heme oxygenase I and superoxide dis-
mutase. It is also important to note that the cigarette smoke itself
is a rich source of free radicals. However, the longevity and biolog-
ical effects of these species has not been fully determined, perhaps
due to their highly reactive nature, and further characterisation of
these species is required (Liu et al., 2011).
The use of enzymatic reactions, electrochemical detection and
chemiluminescent indicator dyes as indicators of cellular ROS
production is widespread. Signiﬁcant recent advances in our
understanding of cardiovascular disease mechanisms have been
made using tools based on these reactions. Certainly, studies using
indicator dyes are plentiful, perhaps as a direct consequence of
their ease of use and the availability of simple microscopy
tools to examine chemiluminescence both in real-time and in ﬁxed
samples. Dyes such as lucigenin (Argacha et al., 2008), dihydroethi-
dium (Ishida et al., 2009; Peluffo et al., 2009), 2,7,-dichloro-
ﬂuorescein (DCF; Shih et al., 2011; Simone et al., 2011) and
dihydrorhodamine (Peluffo et al., 2009) have all been used to
quantify ROS production in cells exposed to various extracts of cig-
arette smoke and relevant to cardiovascular disease progression.6. Exposing in vitro models to cigarette smoke
One of the challenges of developing relevant cardiovascular dis-
ease models lies not in the model per se but in the means by which
the cells are exposed to cigarette smoke and its extracts. Cigarette
smoke is a complex and dynamic mixture of more than 5,600 indi-
vidual chemical constituents (Perfetti and Rodgman, 2011), and
these can be found partitioned in the vapour and particulate
phases of the whole cigarette smoke. There is no ideal method of
exposing cardiovascular cells to cigarette smoke constituents in a
manner that accurately models the in vivo situation. Most com-
monly however, cells may be exposed to the particulate phase of
the smoke by trapping these components on a Cambridge ﬁlter
pad. The trapped particulate is then resuspended in an organic sol-
vent such as dimethylsulphoxide (DMSO) and applied to cells in
submerged culture (Fig. 2A). Since exposure to cigarette smoke
particulate matter contributes substantially to the link between
smoking and cardiovascular mortality (Pope et al., 2009), this
methodmay provide a relevant exposure system for cardiovascular
Fig. 2. Cigarette smoke exposure systems for use with in vitromodels of cardiovascular disease. (A) cells in submerged culture may be exposed to cigarette smoke particulate
by capturing the particulate phase on a Cambridge ﬁlter pad, eluting the trapped matter in an organic solvent (e.g. DMSO) before diluting it and applying it to cells. (B) the
particulate and gas phases may be trapped and used as an exposure agent by bubbling the whole smoke through an impinger containing an inorganic solvent such as culture
media or phosphate buffered saline. As in A, this is diluted before application to submerged cells. (C) some studies have used human sera as an exposure agent to determine
the effects of cigarette smoking on the cardiovascular system. PM, particulate matter. CSE, cigarette smoke extract. Figure adapted from Adamson et al. (2011). In vitroModels
of Chronic Obstructive Pulmonary Disease (COPD), Bronchitis, Martin-Loeches (Ed.), ISBN: 978–953-307–889-2.
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examination of the contribution of the effects of vapour phase
components on cardiovascular cells. To facilitate exposure to these
components, the whole smoke can be passed through an inorganic
liquid such as culture media or phosphate buffered saline (Fig. 2B).
This captures in solution the water-soluble components of both the
particulate and vapour phases, and of course if desired the partic-
ulate phase components can be removed by ﬁltration. What is
missing from this approach, however, is capture of the hydrophilic
components of the cigarette smoke.
Whichever smoke agent is used, one issue concerning the pro-
duction of these cigarette smoke extracts is the standardisation
of their production such that ﬁndings may be reproduced in other
laboratories. With respect to particulate matter, the International
Organization for Standardization (ISO) has laid out standards
which deﬁne how cigarettes should be smoked, in terms of the
length of a puff (2 s), the puff volume (35 ml) and the frequency
of puffs (once per min). When using more intense smoking re-
gimes, for example those suggested by other bodies such as the
Massachusetts Department of Public Health (a 40 ml puff over
2 s, twice per min), different levels of toxicants are found in the cig-
arette smoke (McAdam et al., 2011). This highlights the importance
of using standard regimes to ensure that toxicant exposure is sim-
ilar between different laboratories.
On the topic of cigarette smoke generation, of further impor-
tance is consideration of the appropriate cigarettes to use, both
for model development and testing and to provide controls against
which comparisons can be made. Many laboratories have used
commercially-available cigarettes for the generation of smoke
extracts. Such an approach however may lead to inter-laboratory
differences since the smoke chemistry of different cigarette brands
is diverse and this can give rise to diversity in cellular responses.For this reason, we suggest that the use of standardised reference
cigarettes, such as the 3R4F reference cigarette (University of Ken-
tucky College of Agriculture; http://www.ca.uky.edu/refcig/
3R4F%20Preliminary%20Analysis.pdf), would provide better uni-
formity of experimental responses both within the same labora-
tory and also between laboratories. With respect to experimental
controls, the biological effects of smoke derived from a PREP
should be compared to that of a conventional, commercially-avail-
able product (Institute of Medicine, 2012).
A further issue concerning the exposure of in vitro models to
cigarette smoke is the metabolic activation of the smoke extracts
and their constituents. Certain cigarette smoke toxicants, for
example benzo(a)pyrene, require metabolic activation in order to
exert their effects (Ma and Lu, 2007). Importantly, many in vitro
cell cultures lack metabolic capacity and this can be circumvented
by either metabolically-activating the cigarette smoke extracts
using other systems with this capacity (e.g. liver hepatocytes or li-
ver extracts) before exposure, by activating the extract using a
mammalian liver microsomal fraction such as S9, or by choosing
primary cultured cells with demonstrated active metabolic path-
ways. An approach that avoids the issue of metabolic activation
of cigarette smoke extracts for in vitro models involves exposing
cells to human sera obtained from smokers and non-smokers
(Fig. 2C). This approach has proven particularly useful, for example,
in gaining mechanistic insight into the role of NO biosynthesis in
the pathogenesis of endothelial dysfunction in cardiovascular dis-
ease (Barua et al., 2001, 2003). Importantly, by performing clinical
measurements of arterial reactivity by measuring ﬂow-mediated
endothelium-dependent vasodilatation in the subjects from whom
the sera were obtained, it was possible to demonstrate a positive
correlation between the clinical and the in vitro effects of cigarette
smoking (Barua et al., 2001) and this may add support to the
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(2011) demonstrated that sera from smokers elicited a stronger
oxidative stress response in endothelial cells than sera from non-
smokers, in terms of ROS production, p47phox translocation to
the plasma membrane, and cyclooxygenase 2 (COX-2) mRNA and
protein expression. Preliminary studies assessing endothelial
migration (an endothelial damage repair model), cytokine secre-
tion and inﬂammatory gene expression are also able to detect dif-
ferences between the endothelial cell’s responses to sera obtained
from smokers and non-smokers (unpublished data).This and the
other prior studies in this area have taken what could be consid-
ered a cross-sectional approach and examined differences between
smokers and non-smokers. In terms of the use of this approach for
determining the biological effects of tobacco products with modi-
ﬁed toxicant yields, an examination of whether these models pos-
sess the ability to discriminate between the sera of individuals
before and after either they quit smoking or switch to a reduced
exposure tobacco product is required.
Regardless of the method of exposure, an area that has received
little attention is that of the duration of exposure to cigarette
smoke. In the majority of in vitro models, cells are exposed to cig-
arette smoke extracts or to sera for short periods, typically around
2–48 h. Smoking-related cardiovascular disease is a disorder which
manifests itself over a prolonged period of time and following
many years of exposure to cigarette smoke. When the chronic nat-
ure of the disease is taken into consideration, the limitations of
such an acute exposure period must be addressed. Technical limi-
tations restrict the length of time in which cells can be cultured
in vitro and this impacts our ability to expose cells to cigarette
smoke for more prolonged periods of time. It is also noteworthy
that most experiments involving cigarette smoke exposure apply
a single dose of a cigarette smoke extract to the cells. Again, the
nature of the in vivo exposure to cigarette smoke in a smoker, in
which the vascular system is exposed to toxicants for brief periods
many times a day, may not be adequately reﬂected in such simple
models.
When seeking to improve cigarette smoke exposures for in vitro
models that better mimic in vivo conditions, insight can perhaps be
gained from models of other cardiovascular disease risk factors.
One such risk factor for example is obstructive sleep apnoea, a dis-
order in which upper airway obstruction causes periodic and
repetitive decreases in blood oxygen saturation during sleep (Par-
ish and Somers, 2004). Similar to cigarette smoking, this repeated
hypoxic insult may induce oxidative stress in the cardiovascular
system, potentially explaining why obstructive sleep apnoea is
strongly associated with atherosclerotic cardiovascular disease
(Lavie, 2003; Parish and Somers, 2004; Priou et al., 2010). In vitro
models of obstructive sleep apnoea have utilised the cyclical nat-
ure of the hypoxic insult to mimic that seen in vivo. For example,
Ryan et al., (2005) demonstrated that periodic exposure of HeLa
cells to hypoxia provided a stronger stimulus for the activation of
nuclear factor kappa-light-chain-enhancer of activated B cells
(NF-jB), an oxidative stress-responsive transcription factor, than
sustained hypoxia. This correlates well with the elevation of the
levels of gene products whose expression is regulated by NF-jB
in obstructive sleep apnoea patients (Ryan et al., 2005). Therefore
potential learnings from this ﬁeld can be obtained by considering
not only how long, but also how often, cells are exposed to ciga-
rette smoke in cardiovascular disease in vitro models.7. Are co-cultures needed to re-create a more realistic vascular
phenotype?
The use of co-culture methodologies is yet another area of
emphasis for the development of predictive models ofcardiovascular disease that increase the ability to simulate in vivo
conditions. The cardiovascular system is not a discrete set of indi-
vidual cell types in isolation or even in close proximity, but is a ser-
ies of interacting cells which communicate and modulate the
activity and processes within other cells. Although not a true co-
culture, perhaps the simplest approach to this issue is the use of
conditioned media. In such studies, a primary cell type (e.g. lung
epithelial cells) is exposed to cigarette smoke or its extracts. Sub-
sequent to this exposure, the culture media is then withdrawn
and used as an exposure agent for a secondary cell type (e.g. vas-
cular endothelial cells). This approach essentially exposes the sec-
ondary cell to protein mediators such as inﬂammatory cytokines
which have been secreted from the cells exposed to cigarette
smoke (e.g. Totlandsdal et al., 2008). Further complexity can be
introduced to this approach by integrating other cell types, such
as liver hepatocytes to provide metabolic capability, into a culture
system to generate a true co-culture (Vozzi et al., 2009). While this
approach has some advantages, it does not possess the ability to
re-create the intimate physical and paracrine coupling of cells
which occurs in vivo. These cell interactions may predominantly
occur at the site of entry of cigarette smoke into the bloodstream
(Boitano et al., 2004), or within the vessel wall itself. For example,
the extremely close proximity of vascular endothelial and smooth
muscle cells facilitates both the electrical and chemical coupling of
the two cell types and this may be important in controlling vessel
function and in the early development of atherosclerotic lesions
(Dora, 2010; Truskey, 2010; Vanhoutte, 2010). Co-culture systems
utilising smooth muscle and endothelial cells have been developed
using a number of approaches including direct culture of the two
cell types and growing each cell type on either side of a membrane
(Truskey, 2010). The ability to culture cells in this way has also lead
to the development of a high-throughput screening system for no-
vel pharmacological agents targeting the cardiovascular system.
While such techniques have yet to be utilised to examine the car-
diovascular effects of cigarette smoke, it is likely that such an ap-
proach would yield a wealth of mechanistic information as well
as provide a powerful testing tool for assessing the biological ef-
fects of smoke from cigarettes with modiﬁed toxicant yields.
Regarding multiple cell types cultured simultaneously, it is also
worthwhile highlighting the potential future use of organotypic
heart slice and whole organ in vitro cultures as tools for examining
the mechanisms underlying the impact of cigarette smoke on car-
diovascular disease progression, as well as for examining changes
in biological effects of smoke derived from PREPs. Such systems
have been used for many years in the assessment of the effects
of novel pharmacological agents on cardiovascular electrophysio-
logical and contractile function (Habeler et al., 2009). An advantage
of these integrated models is that they can maintain their physio-
logical integrity for long periods of time. Such models have yet to
be used in research in atherosclerotic cardiovascular disease, but
they may lend themselves well to modelling the long-term disease
processes which occur in smoking-related cardiovascular disease.
Clearly, a number of in vitro cardiovascular disease models have
the potential for use in an approach to assess the biological effects
of cigarette smoke from modiﬁed cigarettes, and these have been
summarised in Table 2. What we have not discussed in this article
are the practicalities of use of these models, particularly in terms of
model validation and experimental standards. With respect to the
latter, any data and conclusions derived from the use of these mod-
els would have greater strength if studies were conducted follow-
ing the principles of Good Laboratory Practise, which would ensure
the quality, integrity and reproducibility of experimental ﬁndings
(Gupta et al., 2006). Model validation is an area which needs a
great deal of development in order to ensure that the models used
are ﬁt-for-purpose, in terms of the model used being relevant to
the disease being examined and linked to pathogenic processes.
Table 2
Summary of in vitro cardiovascular disease models described in this review. DHE, dihydroethidium; DCF, 2,7,-dichloroﬂuorescein.
Model Readout Advantages Disadvantages
Endothelial markers Gene and/or protein expression
(e.g. sICAM-1, vCAM-1, IL-6, IL-
8, selectins)
Easy to measure levels of multiple
genes and proteins involved in
pathogenesis
Markers may not be predictive of cardiovascular disease
Potential for novel biomarker
identiﬁcation




Horizontal migration rate Simple high-throughput assay Model may not accurately reﬂect in vivo endothelial damage
Assessment of extracellular matrix
and cell-cell interactions




Chemotactic vertical migration Versatile assay which can measure
chemotaxis, haptotaxis and
chemokinesis
Cells migrating in absence of other cell types
Endothelial
angiogenesis
2-D angiogenic tube formation Simple and quick assay Assay is a short-term representation of a long-term physiological
process
Possible automation for kinetic
analyses








Models a process directly involved
in lesion development and
progression
Gold standard method involves the use of radiation, which is
expensive and requires infrastructure for safe use Nicotine is a
confounding factor which stimulates proliferation and chemotaxis
Monocyte recruitment Attachment of monocytes to an
endothelial layer
Models a process directly involved
in early atherogenesis
In vitro environment may lack key components involved in
recruitment
Cells cultured in ﬂow
conditions
Many possible including gene
and protein expression, and
monocyte recruitment
Can monitor multiple endpoints in a
single assay
Technically-demanding and low throughput
Generates physiologically-relevant




Accumulation of lipids in
macrophages
Models a process directly involved
in early lesion development
Technically difﬁcult to control for oxidation of lipids in vitro or
ex vivo
ROS detection Dye ﬂuorescence (lucigenin,
DHE, DCF, dihydrorhodamine)
Simple assessment of general
oxidation
Sensitivity and speciﬁcity of some dyes has been questioned
Application to several disease
endpoints
Dyes themselves may cause cellular stress
Co-cultures Endpoints as described above
for mono-culture models
Better simulates a physiological
state/environment in which cell-cell
interactions can occur
Technically demanding to grow two cell types with different
environment requirements together
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reproducible and repeatable and that similar ﬁndings could be ob-
tained from independent laboratories using the same model and
test agents. Of further importance is veriﬁcation of the identity of
the cells used in any given model, to ensure that they are in fact
authentic and what the investigator believes them to be (Freshney,
2008).
8. A brief word on in vivo models
While in vitromodels are powerful assessment tools, a thorough
testing strategy may be enhanced with in vivomodels. In the realm
of cardiovascular disease studies, many animal models have been
used over several decades and include a range of species from pi-
geons to non-human primates. Early animal models relied on ath-
erogenic diets to drive the pathogenesis of cardiovascular disease
and typically were time-consuming and expensive. However,
important understandings of disease processes resulted from the
use of these models. Current in vitro models are poor predictors
of events that lead to plaque formation, destabilisation, rupture
and thrombotic events. Thus, in vivo models provide a systems ap-
proach to understanding a disease process which cannot be fully
reproduced using in vitro models or not permitted and/or possible
in human studies.
With the development of genetically altered mice, the scientiﬁc
understanding of disease mechanisms and processes has greatly
advanced the ﬁeld. These understandings would have been consid-
erably delayed using strictly in vitro laboratory assays. For exam-
ple, consider the apoE/ mouse model of atherosclerosis. The
apoE/ mouse lacks apolipoprotein E, a key protein involved in
the clearance of LDL including b-very low density lipoproteins (b-VLDL). These mice rapidly develop atherosclerotic plaques that clo-
sely resemble those of humans both in location and severity. The
durations of experiments and their related costs are considerably
decreased compared to many other models of cardiovascular dis-
ease. Even in a well described animal model, some limitations
are present. In the case of the apoE/mouse model, these animals
typically do not develop thrombi seen in humans. Also, initial pla-
que development occurs at the aortic sinus, an area not particularly
of concern in humans. Despite these drawbacks, the apoE/
mouse model continues to provide valuable information related
to the development of cardiovascular disease mechanisms.
The Institute of Medicine has clearly stated that as part of a
thorough testing strategy ‘‘Animal models. . .can contribute to
the. . . development of a scientiﬁc basis for designing and evaluat-
ing harm reduction products’’ (Stratton et al., 2001). The Institute
of Medicine also states that ‘‘animal models are limited’’ and rec-
ommend the ‘‘development of appropriate animal models’’ to
study the pathogenesis of disease. The value of informative and
quality animal models of cardiovascular disease is crucial to study
the effects of smoking on disease processes. At the same time, it is
also important to emphasise the importance of the ‘‘3Rs’’, reﬁne-
ment, reduction and replacement in animal research. The use of
in vivo models should ultimately enhance the development and
use of in vitro assays to study and assess the effects of cigarette
smoke exposure on cardiovascular disease in a complementary
framework.
9. Summary
Cigarette smoking poses a substantial risk to cardiovascular
health, a risk which could potentially be reduced by the production
I.M. Fearon et al. / Toxicology in Vitro 27 (2013) 513–522 521of modiﬁed risk tobacco products with altered toxicant yields. Any
reduction in risk needs to be substantiated using a framework of
pre-clinical and clinical studies designed to characterise the mod-
iﬁed risk and a pivotal component of this framework is the use of
in vitromodels. This was further emphasised with the recent report
by the Institute of Medicine (2012) examining the scientiﬁc stan-
dards for studies on modiﬁed risk tobacco products. While our
knowledge of how these in vitro models operate is strong, further
development is necessary in areas such as cellular metabolic
capacity, cell-to-cell interactions, co-culture models, ﬂow-based
vs. static models and exposure systems. The use of in silico model-
ling as a predictive tool is also a potential area for future explora-
tion. Finally, despite the large number of in vitro models described
in this review and elsewhere, none are fully validated or currently
required in regulatory testing. This highlights the need to validate
and standardise methods for in vitro disease models, not only of
cardiovascular disease but also of other smoking-related diseases.Conﬂict of interest statement
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